HC Wainwright Has Optimistic Outlook of ACHV Q3 Earnings

Achieve Life Sciences, Inc. (NASDAQ:ACHV) – HC Wainwright lifted their Q3 2026 EPS estimates for shares of Achieve Life Sciences in a research note issued on Tuesday, August 11th. HC Wainwright analyst B. Folkes now forecasts that the biopharmaceutical company will post earnings of ($0.22) per share for the quarter, up from their prior estimate of ($0.23). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Achieve Life Sciences’ current full-year earnings is ($0.81) per share. HC Wainwright also issued estimates for Achieve Life Sciences’ Q4 2026 earnings at ($0.26) EPS, FY2026 earnings at ($1.54) EPS and FY2027 earnings at ($0.79) EPS.

Several other equities research analysts have also commented on ACHV. Weiss Ratings raised shares of Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. UBS Group reissued a “buy” rating on shares of Achieve Life Sciences in a report on Wednesday. Canaccord Genuity Group set a $13.00 target price on shares of Achieve Life Sciences and gave the company a “buy” rating in a research report on Monday, April 20th. Wall Street Zen raised shares of Achieve Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, May 17th. Finally, Raymond James Financial reiterated a “strong-buy” rating and issued a $18.00 price target on shares of Achieve Life Sciences in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Achieve Life Sciences has an average rating of “Buy” and a consensus target price of $15.00.

Achieve Life Sciences Stock Down 1.2%

ACHV stock opened at $6.69 on Thursday. The company has a market cap of $686.80 million, a price-to-earnings ratio of -4.32 and a beta of 2.24. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.62 and a current ratio of 2.62. The business’s 50-day moving average is $6.03 and its two-hundred day moving average is $4.90. Achieve Life Sciences has a fifty-two week low of $2.45 and a fifty-two week high of $7.11.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.64).

Institutional Investors Weigh In On Achieve Life Sciences

Institutional investors and hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC bought a new position in shares of Achieve Life Sciences during the first quarter worth $32,000. Sender Co & Partners Inc. bought a new stake in Achieve Life Sciences in the 2nd quarter valued at $56,000. Magnolia Capital Advisors LLC purchased a new stake in Achieve Life Sciences in the 4th quarter worth $64,000. Bank of America Corp DE lifted its stake in Achieve Life Sciences by 39.9% in the 2nd quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock worth $76,000 after purchasing an additional 9,617 shares in the last quarter. Finally, Jefferies Financial Group Inc. bought a new position in shares of Achieve Life Sciences during the 4th quarter valued at about $84,000. Institutional investors own 33.52% of the company’s stock.

More Achieve Life Sciences News

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $12 price target, well above recent trading levels. Its estimates still project Achieve becoming profitable, with positive EPS forecast for 2028 through 2030. HC Wainwright analyst estimates
• Positive Sentiment: Achieve Life Sciences’ shares have nearly tripled over the past year, reflecting investor optimism about its pipeline and the potential commercial opportunity if the company can achieve profitability. Achieve Life Sciences stock has nearly tripled in the last year
• Neutral Sentiment: Reported short interest was listed at zero shares, implying no meaningful short-position data or short-squeeze catalyst in the latest report.
• Negative Sentiment: The company reported a second-quarter loss of $0.80 per share, substantially worse than the consensus loss estimate of $0.16. The miss reinforces concerns that Achieve remains well short of profitability. Achieve Life Sciences Reports Second Quarter 2026 Financial Results
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for 2028, 2029 and 2030 to $0.23, $0.97 and $1.47, respectively, from $0.24, $1.00 and $1.51. Although the firm remains bullish, the downward revisions suggest a somewhat slower profit ramp.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.